SLAMF7 and cancer: The data presented here demonstrate that surface expression of SLAMF7 on hematopoietic cancer cells, specifically on B cell malignant cells, is not required for phagocytosis upon CD47 blocking treatment, nor upon combination treatment with rituximab.